Click Now!

UK’s top sports supplement banned over side-effect fears

Thought to have potentially lethal side-effects in conjunction with the stimulant DMAA, Britain’s top sports supplement has been banned.

Thought to have potentially lethal side-effects in conjunction with the stimulant DMAA, Britain’s top sports supplement has been banned.

Jack3d, once easily obtained via internet stores and even some sports retailers in the UK, has been the subject of much commotion concerning the supplement’s potentially lethal effects.
The stimulant in Jack3d, dimethylamylamine or DMAA, has been linked to such adverse side-effects as high blood pressure, headaches, vomiting, stroke and even a death.

Athlete’s with heavy exercise regimens prefer to use this and similar supplements with DMAA due to the stimulant’s effects that allow these athletes to train harder and longer.

Britain’s Medicines and Healthcare products Regulatory Agency, a healthcare overseer for athletic and training supplements, came to the decision to impose the ban when a man died in Australia after utilizing the supplement he purchased online. Similar bans have since followed in the US and Australia.

DMAA is also responsible for more failed drug tests administered on high level athletes than any other substance, with 137 offences total in the last two years alone.

Not only Jack3d is off the market, the UK MHRA won against an anonymous retailer’s appeal to keep Jack3d on the market, effectively banning all products containing DMAA from being sold or shipped to the UK.

Those retailers who are found to continue selling the supplements that contain DMAA will receive written notice, reminding them of the drug’s illicit scheduling. Further lack of action on a retailer’s part would result in legal action.

OCA News Editor

Christian Bright is a professional sports commentator with keen interests in football, tennis and horse racing. His experience in the reporting on professional sports makes him a key asset to OCA’s coverage of athletic events and matches.

COMMENTS

comments